Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Filings indexed 226 across all filing types
Latest filing 2022-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-13 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2022, reporting the financial results for the quarter ended March 31, 2022. It includes a press release as Exhibit 99.1 announcing quarterly financial results. The document is relatively short (3748 characters) and primarily serves as a current report to announce earnings results rather than providing detailed financial statements or comprehensive analysis. According to the definitions, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document fits best as an Earnings Release (ER).
2022-05-10 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-29 English
10-K
Annual Report FY 2021
2022-03-18 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-11 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.